Trial Profile
A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Otilimab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 14 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 02 May 2018 According to a MorphoSys media release, data publication anticipated in 2018.